CD8A and COVID-19: Limitations of our study include that we focused only on vaccine and infection induced binding and NAb responses, which are important contributors to protecting against SARS-CoV-2 infection and mild-moderate COVID.2, 5 We did not evaluate CD4+ and CD8+ T lymphocyte responses, which probably attenuate the clinical severity of COVID-19.